MapLight Therapeutics, Inc.
MPLTNasdaq
$37.87
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↑ +106.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7B
Enterprise Value
$1.4B
P/E
—
P/S
—
P/B
4.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$199.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-49.9%
ROIC
—
Debt / Equity
—
Net Cash
$310.1M
Return 1Y
—
Company profile
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our principal executive offices are located in Redwood City, California.
- CEO
- Christopher A. Kroeger
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 109
- Headquarters
- California
- Website
- maplightrx.com/
Management & directors
- Foff Erin PennockChief Medical Officer
- Gillis JonathanCAO and Interim CFO
- Hanson KristopherGeneral Counsel
- Kreitzer AnatolChief Discovery Officer
- Kroeger Christopher A.Chief Executive Officer
- Lillie James WoodruffChief Scientific Officer
- Setia VishwasChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
MPLT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.34↓ -95.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$82.9M | -$169.1M |
| Net income | -$77.6M | -$161.2M |
| Diluted EPS | -$105.38 | -$18.56 |
| Operating cash flow | -$78.8M | -$138.1M |
| Free cash flow | -$79.6M | -$138.6M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q3 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | -$20.9M | — | -$23.5M | — | -$31.5M | — | -$64.5M |
| Net income | -$18.4M | -$19.0M | -$21.2M | -$22.3M | -$29.8M | -$29.4M | -$79.5M | -$60.7M |
| Diluted EPS | — | -$25.08 | — | -$29.33 | — | -$37.18 | — | -$1.34 |
| Operating cash flow | — | — | — | -$25.6M | — | — | — | -$51.2M |
| Free cash flow | — | — | — | — | — | — | — | -$51.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-17 | GILLIS JONATHAN· CAO and Interim CFO | Sale | 16,969 | $37.61 | $638,204.09 | filing |
| 2026-07-17 | Kroeger Christopher A.· Chief Executive Officer | Sale | 16,779 | $37.90 | $635,924.10 | filing |
| 2026-07-17 | Kreitzer Anatol· Chief Discovery Officer | Sale | 14,140 | $37.70 | $533,078.00 | filing |
| 2026-07-17 | Foff Erin Pennock· Chief Medical Officer | Sale | 3,656 | $37.90 | $138,562.40 | filing |
| 2026-07-17 | Kreitzer Anatol· Chief Discovery Officer | Sale | 2,833 | $37.05 | $104,962.65 | filing |
| 2026-07-17 | Lillie James Woodruff· Chief Scientific Officer | Sale | 2,077 | $37.90 | $78,718.30 | filing |
| 2026-07-17 | Hanson Kristopher· General Counsel | Sale | 1,130 | $37.90 | $42,827.00 | filing |
| 2026-07-17 | GILLIS JONATHAN· CAO and Interim CFO | Sale | 900 | $38.17 | $34,353.00 | filing |
| 2026-07-17 | GILLIS JONATHAN· CAO and Interim CFO | Sale | 600 | $36.51 | $21,906.00 | filing |
| 2026-07-17 | Kreitzer Anatol· Chief Discovery Officer | Sale | 200 | $38.39 | $7,678.00 | filing |
| 2026-07-16 | Kroeger Christopher A.· Chief Executive Officer | Sale | 40,899 | $36.46 | $1.5M | filing |
| 2026-07-16 | Kroeger Christopher A.· Chief Executive Officer | Sale | 28,091 | $37.26 | $1.0M | filing |
| 2026-07-16 | Foff Erin Pennock· Chief Medical Officer | Sale | 9,163 | $36.46 | $334,082.98 | filing |
| 2026-07-16 | Kreitzer Anatol· Chief Discovery Officer | Sale | 7,464 | $36.66 | $273,630.24 | filing |
| 2026-07-16 | GILLIS JONATHAN· CAO and Interim CFO | Sale | 6,979 | $36.66 | $255,850.14 | filing |
| 2026-07-16 | Foff Erin Pennock· Chief Medical Officer | Sale | 5,865 | $37.26 | $218,529.90 | filing |
| 2026-07-16 | Lillie James Woodruff· Chief Scientific Officer | Sale | 5,009 | $36.45 | $182,578.05 | filing |
| 2026-07-16 | Hanson Kristopher· General Counsel | Sale | 4,776 | $36.45 | $174,085.20 | filing |
| 2026-07-16 | Lillie James Woodruff· Chief Scientific Officer | Sale | 3,526 | $37.26 | $131,378.76 | filing |
| 2026-07-16 | Hanson Kristopher· General Counsel | Sale | 3,331 | $37.26 | $124,113.06 | filing |
| 2026-07-16 | Kreitzer Anatol· Chief Discovery Officer | Sale | 1,592 | $37.44 | $59,604.48 | filing |
| 2026-07-16 | GILLIS JONATHAN· CAO and Interim CFO | Sale | 1,476 | $37.44 | $55,261.44 | filing |
| 2026-07-16 | Kroeger Christopher A.· Chief Executive Officer | Sale | 92 | $37.96 | $3,492.32 | filing |
| 2026-07-16 | Foff Erin Pennock· Chief Medical Officer | Sale | 19 | $37.96 | $721.24 | filing |
| 2026-07-16 | Lillie James Woodruff· Chief Scientific Officer | Sale | 12 | $37.96 | $455.52 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.